The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, announce partnerships with Swiss giant Roche and its compatriot firm OrigiMed, a precision medicine company. The collaboration aims to expand the pan-solid tumor payment service mode, designed to alleviate the financial burden on Chinese patients with positive NTRK.
Partnership Objectives
Roche’s TRK/ROS1 inhibitor Rozlytrek (entrectinib) was approved in China in July this year, offering a novel therapy for NTRK-fusion-positive cancer patients. OrigiMed has launched an Internet Hospital NTRK outpatient unit, providing pan-cancer NTRK detection technologies and outpatient services for patients suited to entrectinib use. PingAn Good Doctor’s upcoming insurance product is expected to cover NTRK gene detection, diagnosis, treatment, and entrectinib costs, further enhancing accessibility to this innovative therapy.
Future Prospects
This strategic collaboration underscores the commitment of PingAn Good Doctor, Roche, and OrigiMed to improving patient outcomes and reducing the financial burden associated with NTRK-fusion-positive cancers. By integrating innovative therapies, precision medicine, and insurance solutions, the partnership aims to provide comprehensive support for patients in China.-Fineline Info & Tech
